UK biotech Autolus Therapeutics has announced that the pivotal Phase II FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult acut 9 December 2022
In a challenging environment for biotech finance, Australian needle-free treatment specialist Vaxxas has raised new money for its COVID-19 vaccine - proof of it 6 December 2022
Research from industry analyst GlobalData has highlighted the extent to which the market capitalization of the largest biopharmaceutical firms has declined in t 5 December 2022
A decade on from the founding of The Cell and Gene Therapy Catapult (CGT Catapult), the UK-based industry accelerator is celebrating its successes. 22 November 2022
Bonum Therapeutics, a biopharma using allosteric regulation to create conditionally active and less toxic medicines, has announced a $93 million Series A financ 16 November 2022
Chinese biotech company Hutchmed is evolving its business strategy, targeting a faster path to profitability amid turbulent economic conditions. 15 November 2022
Times are tough for cell medicine specialist Rubius Therapeutics (Nasdaq: RUBY), with the firm announcing plans to slash its workforce by 84%, part of a drastic 3 November 2022
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news